Patients with metastatic breast cancer facing disparities in care can benefit from telehealth services by saving time and receiving much of their care at home through virtual appointments, patient portal communications, and online education.
Patients with metastatic breast cancer facing disparities in care can benefit from telehealth services by saving time and receiving much of their care at home through virtual appointments, patient portal communications, and online education.
Authors from the Community Oncology Alliance explore what could be next for practices seeking continual improvement in the Oncology Care Model, a multimillion dollar, years-long program that has helped community oncology practices transform...
Authors from the Community Oncology Alliance explore what could be next for practices seeking continual improvement in the Oncology Care Model, a multimillion dollar, years-long program that has helped community oncology practices transform...
Ronaé McLin, MPH, and colleagues explore the benefits and limitations of collecting HCRU within a clinical trial, as well as recommendations for how to do so in a way that will yield the most useful data.
Ronaé McLin, MPH, and colleagues explore the benefits and limitations of collecting HCRU within a clinical trial, as well as recommendations for how to do so in a way that will yield the most useful data.
Joshua M. Liao, MD, MSc, describes population health definitions and articulates an opportunity for providers to align their work under the concept of population health care.
Joshua M. Liao, MD, MSc, describes population health definitions and articulates an opportunity for providers to align their work under the concept of population health care.
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses reasons why pharmaceutical waste management is emerging as a new major public and environmental health concern.
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses reasons why pharmaceutical waste management is emerging as a new major public and environmental health concern.
Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.
Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.